Clinical trial uncertainty
Outcomes are unpredictable
- Materiality
- high
Alligator Bioscience
Alligator Bioscience is a Swedish biotech company focused on developing innovative antibody-based medicines for cancer immunotherapy. The company specializes in tumor-directed immunotherapies, leveraging its expertise in the CD40 field and antibody engineering technologies. Alligator aims to advance its drug candidates to Phase 2 clinical studies, making them attractive for out-licensing to Big Pharma for further development and commercialization. The company operates primarily from its headquarters in Lund, Sweden, and collaborates with Contract Development and Manufacturing Organizations (CDMOs) for production.
11
0.88
0.87
| % | |
|---|---|
| Immunotherapies | 50% Includes tumor-directed therapies providing long-lasting immunity |
| Antibody Engineering | 20% Technologies for developing unique antibody-based treatments |
| Licensing Agreements | 30% Out-licensing of drug candidates to Big Pharma |
Alligator Bioscience primarily targets large pharmaceutical companies interested in licensing innovative cancer...
- Pharmaceutical Companiesprimary
License drug candidates for late-stage development
- Biotech Firmssecondary
Collaborate on early-stage development and technology
- Research Institutionsemerging
Engage in joint research on cancer immunotherapy
Alligator Bioscience is headquartered in Lund, Sweden, and operates primarily within the European market...
- •Headquartered in Lund, Sweden
- •Operates primarily within the European market
- •Collaborates with international partners for clinical development
- •Outsources manufacturing to CDMOs for specialized expertise
Alligator Bioscience's strategic priorities include advancing its lead asset, mitazalimab, through clinical...
01
Advance mitazalimabmedium-term
To achieve clinical proof-of-concept
02
Out-license drug candidatesshort-term
For further development by Big Pharma
03
Leverage antibody technologieslong-term
To create differentiated therapies
Alligator Bioscience faces several risks, including the uncertainty of clinical trial outcomes and reliance on partners...
Reliance on partners
For commercialization and development
- Materiality
- high
Intense competition
Rapid technological advancements
- Materiality
- medium
Irregular cash flow
Dependent on licensing events
- Materiality
- high
Revenue recognition
Significant on reported revenue
Impairment testing
Critical for asset valuation
Currency fluctuations
Influences financial results
CellaVision
CEVI.ST · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Vimian Group
VIMIAN.ST · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Active Biotech
ACTI.ST · Health Care
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications.
BioArctic
BIOA-B.ST · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
: 11/08/2026